Welcome to the Market Access Radar Podcast, your expert briefing on the latest in Market Access and Health Economics in the Bio-Pharmaceutical Industries.
(4) Policy Briefing: A new agenda for CMS, the Biden White House, and a Democratic Congress
We're finally back with a new season for the Radar Podcast, pharma's flagship intelligence briefing on all things market access, real-world evidence, and payer strategy. This program is brought to you by the experts in Certara's global Evidence & Access practice. In this episode, we're discussing the Biden administration's policy positions, the fate of Trump-era CMS proposals, and what the new majority in the 117th Congress will mean for the biopharma industry. Your host for this week is Max Goldstein, Director of Business Development, speaking to Ulrich Neumann, Senior Director, Access and Commercial Strategy. For any questions on the topics discussed today, please contact email@example.com or download our latest whitepapers here: https://www.certara.com/evidence-access/us-managed-markets/key-trends-us-specialty/--- Send in a voice message: https://anchor.fm/market-access-radar/message
7 Feb 2021